JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  01:48 2022-07-01 pm EDT
177.97 USD   +0.26%
01:23pDOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
DJ
03:32aPharmaceutical companies still have the upper hand
06/30Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal

05/20/2022 | 04:12pm EDT

The Justice Department's bankruptcy watchdog is objecting to Johnson & Johnson's talc subsidiary retention of former Solicitor General Neal Katyal for a high-stakes appeal over a legal strategy that moved thousands of talc injury suits to chapter 11.

The U.S. Trustee, a Justice Department unit monitoring the nation's bankruptcy courts, said in a Friday court filing that J&J's talc unit hasn't demonstrated the cost of Mr. Katyal's services are reasonable or needed since the company has already hired other top law firms. Mr. Katyal, now a partner at the Hogan Lovells law firm, has an hourly rate of $2,465, according to court documents.

The appeal Mr. Katyal and other Hogan Lovells lawyers are being retained for concerns J&J's LTL Management LLC, which was created to file chapter 11 and drive settlements of about 38,000 talc injury suits. The strategy, which is being opposed by plaintiffs' lawyers, was approved by a bankruptcy judge earlier this year.

A judge earlier denied U.S. Trustee objections to LTL's retention of firms Jones Day and Skadden, Arps, Slate, Meagher & Flom LLP.


Write to Jonathan Randles at jonathan.randles@wsj.com


(END) Dow Jones Newswires

05-20-22 1812ET

All news about JOHNSON & JOHNSON
01:23pDOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
DJ
03:32aPharmaceutical companies still have the upper hand
06/30Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for..
AQ
06/30Hywin Holdings, FactSet Launch Global Health Care Index
MT
06/29NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
06/29Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
MT
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 505 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,7x
Yield 2022 2,51%
Capitalization 467 B 467 B -
EV / Sales 2022 4,75x
EV / Sales 2023 4,47x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 177,51 $
Average target price 187,28 $
Spread / Average Target 5,50%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.46%467 100
PFIZER, INC.-13.73%294 179
ELI LILLY AND COMPANY16.94%291 859
ROCHE HOLDING AG-15.97%272 586
ABBVIE INC.13.12%270 651
NOVO NORDISK A/S7.10%251 273